Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports
Introduction Chronic insomnia affects 5% to 10% of the US population, increasing the demand for treatment options and the corresponding research to prove their validity.1 This review compares recommendations from 3 clinical guidelines and summarizes hypnotic medications, including their newly report...
Main Authors: | Del Rio Verduzco Alejandro PharmD, MS, Salari Ahva BS, Haghparast Parna PharmD, BCPS |
---|---|
Format: | Article |
Language: | English |
Published: |
American Association of Psychiatric Pharmacists
2023-10-01
|
Series: | Mental Health Clinician |
Subjects: | |
Online Access: | https://theijpt.org/doi/pdf/10.9740/mhc.2023.10.244 |
Similar Items
-
MELATONIN DAN MELATONIN RECEPTOR AGONIST SEBAGAI PENANGANAN INSOMNIA PRIMER KRONIS
by: Ni Luh Putu Ayu Maha Iswari, et al.
Published: (2013-04-01) -
Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience
by: Matsumura T, et al.
Published: (2019-02-01) -
Eszopiclone versus zopiclone in the treatment of insomnia
by: Luciano Ribeiro Pinto Jr, et al.
Published: (2016-01-01) -
Non‐24‐hour sleep‐wake disorder successfully treated with the combination of ramelteon and suvorexant in a case of autism spectrum disorder
by: Masaaki Iwata, et al.
Published: (2020-12-01) -
Pharmacologic Treatment Options for Insomnia in Patients with Schizophrenia
by: Lauren Stummer, et al.
Published: (2018-08-01)